Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy.

MLA

Putzu, Carlo, et al. “Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy.” Current Oncology (Toronto, Ont.), vol. 31, no. 9, Aug. 2024, pp. 4955–67. EBSCOhost, https://doi.org/10.3390/curroncol31090367.

APA

Putzu, C., Serra, R., Campus, R., Fadda, G. M., Sini, C., Marongiu, A., Ginesu, G. C., Fois, A. G., Palmieri, G., Zinellu, A., Cossu, A., & Paliogiannis, P. (2024). Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy. Current Oncology (Toronto, Ont.), 31(9), 4955–4967. https://doi.org/10.3390/curroncol31090367

Chicago

Putzu, Carlo, Riccardo Serra, Rachele Campus, Giovanni Maria Fadda, Claudio Sini, Andrea Marongiu, Giorgio Carlo Ginesu, et al. 2024. “Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy.” Current Oncology (Toronto, Ont.) 31 (9): 4955–67. doi:10.3390/curroncol31090367.